Risk-Based Monitoring in Fixed-Budget Trials
From the Confidence Medical Affairs Desk by Inna Nemirovskaya Concentrating Oversight Where It Protects Study Credibility In extremely low-budget, full-service clinical trials, monitoring strategy ceases to be a matter of preference. It becomes structural. When financial flexibility is absent, oversight must be designed with precision, because every monitoring decision directly competes with another operational priority. […]
Important Protocol Deviations vs. Serious Breaches: What ICH GCP E6(R3) Means for Global Trial Teams
From the Confidence Medical Affairs Desk by Tatiana Dumpis Clinical trials become more global, digital, and risk-based. One key distinction is important for sponsors, CROs, and investigators: the difference between an important protocol deviation and a serious breach. The two concepts overlap, but they are not the same. Confusing them can lead to delayed escalation, […]
Infectious Disease Trials: Where Safety and Speed Converge
Infectious-disease research presents a unique intersection of scientific urgency and operational precision. Outbreak-driven timelines, evolving pathogens, and strict safety oversight make this therapeutic area complex to manage effectively. The scale of the global infectious-disease burden continues to climb: the WHO estimates that infectious diseases account for one in four deaths worldwide, with lower respiratory infections […]
Utilizing Advertisement and Patient Recruitment Companies in Rare Disease Studies Enrollment in Rare Diseases: Beyond Traditional Boundaries
Rare disease trials consistently face one of the most stubborn bottlenecks in clinical research: finding enough eligible patients to complete the study on time. Even when sites are strategically selected and advocacy groups are fully engaged, gaps often remain. Patients may be geographically dispersed, underdiagnosed, or unaware that clinical trials exist as a treatment option. […]
Global Study Rescue: Full Study Rejuvenation
When a global clinical trial falters, the consequences ripple across continents. Recruitment slows in multiple regions, data flow becomes irregular, monitoring gaps widen, and the trial’s scientific and financial integrity is placed at risk. Unlike localized underperformance, which can often be corrected with targeted adjustments, global studies require something far more comprehensive: a full rejuvenation […]